Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA Study

International Journal of Clinical Practice

Volumn 60, Issue 11, 2006, Pages 1364-1370

  Barrios, V ^a   Escobar, C ^a   Navarro, A ^b   Barrios, L ^a   Navarro cid, J ^a   Calderon A ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Antihypertensive drugs; Dihydropyridines; Hypertension; Lercanidipine; Tolerability

Indexed keywords

LERCANIDIPINE;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; FLUSHING; FOLLOW UP; HEADACHE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 33749873666     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01176.x     Document Type: Article

References (29)

1. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat. Q. 1988; 41: 155-78.
2. Thom TJ. International mortality from heart disease: Rates and trends. Int. J. Epidemiol. 1989; 18 (Suppl. 1): S20-8.
3. Stewart AW, Kuulasmaa K, Beaglehale R, for the WHO MONICA Project. Ecological analysis of the association between mortality and major risk factors of cardiovascular disease. The World Health Organization MONICA Project. Int J Epidemiol 1994; 23: 505-16.
4. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: Is the 'rule of halves'still valid? J Hum Hypertens 1997; 11: 213-20.
5. Black HR. The burden of cardiovascular disease: Following the link from hypertension to myocardial infarction and heart failure. Am J Hypertens 2003; 16 (Suppl. 1): 4S-6S.
6. Cushman WC. The burden of uncontrolled hypertension: Morbidity and mortality associated with disease progression. J Clin Hypertens (Greenwich) 2003; 5 (Suppl. 2): 14-22.
7. Sica DA. Are current strategies for treating hypertension effective? J Clin Hypertens (Greenwich) 2003; 5 (Suppl. 2): 23-32.
8. Chobanian AV, Bakris GL, Black HR, et.al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003; 289: 2560-72.
9. European Society of Hypertension-European Society of Cardiology Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
10. Gasser R, Köppel H, Klein W. Lercanidipine, a new third generation C-antagnist in the treatment of hypertension. J Clin Basic Cardiol 1999; 2: 169-74.
11. McClellan KJ, Jarvis B. Lercanidipine: A review of its use in hypertension. Drugs 2002; 60: 1123-40.
12. Epstein M. Lercanidipine: A novel dihydropyridine calcium-channel blocker. Heart Dis 2001; 3: 398-407.
13. Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press Suppl 1998; 2: 10-17.
14. Meredith PA. Lercadinidipine: A novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Exp Opin Invest Drugs 1999; 8: 1043-62.
15. Barrios V, Honorato J, Llisterri JL, Calderon A, Navarro A, de la Figuera M. Comparative tolerability of lercanidipine with other calcium channel blockers: The TOLERANCE study. J Clin Hypertens 2006; 8 (Suppl. A): A74.
16. Cherubini A, Fabris F, Ferrari E et.al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: The ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 37: 203-12.
17. Barrios V, Navarro A, Esteras A et.al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Blood Press 2002; 11: 95-100.
18. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. J Hypertens 1998; 16: 1831-8.
19. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A; COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15: 932-40.
20. Cherubini A, Fabris F, Ferrari E et.al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: The ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 37: 203-12.
21. Romito R, Pansini MI, Perticone F, Antonelli G, Pitzalis M, Rizzon P. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: The Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003; 5: 249-53.
22. James IG, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16: 605-10.
23. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006; 24: 185-92.
24. Bang LM, Chapman TM, Goa KL. Lercanidipine. A review of its efficacy in the management of hypertension. Drugs 2003; 63: 2449-72.
25. de la Sierra A, Ruilope LM, Coca A, Luque-Otero M. Relationship between cardiovascular risk profile and anti-hypertensive drug use. GEDEC (Spanish group of cardiovascular studies). Med Clin (Barc) 2000; 115: 41-45.
26. Barrios V, Campuzano R, Peña G et.al. Coronary risk stratification in hypertensive patients attended in primary care setting and its relationship with atihypertensive treatment. DIORISC study. Hipertension 2002; 19: 114-20.
27. Hosie J, Wilklund I. Managing hypertension in general practice: Can do we better?. J Hum Hypertens 1995; 9: S15-8.
28. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1997; 349: 454-7.
29. Blood Pressure Lowering Treatment Trialist'Collaboration. Effects of ACE inhibitors, calcium channel blockers, and other blood pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-64.